Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals, Inc. is a New York-based biotechnology company listed on the NYSE under the ticker ATNM. It focuses on developing targeted radiotherapy approaches, including antibody radiation conjugates, for patients with cancers that have not responded to existing treatments. The company’s clinical-stage programs include Actimab-A, which is being studied in myeloid malignancies such as acute myeloid leukemia and myelodysplastic syndromes, and Iomab-ACT, which is designed to support access to cellular therapies including CAR-T and certain gene therapies for blood cancer and non-malignant hematologic disorders. Actinium is also advancing Iomab-B as an induction and conditioning agent ahead of bone marrow transplant in relapsed and refractory AML. Its pipeline further includes ATNM-400, a preclinical radiotherapy candidate for prostate cancer, and the company works with the National Cancer Institute on development efforts for Actimab-A and related myeloid malignancy programs.

Jump directly to the stock analysis sections supported by the latest available data.